# Markers of Antiviral Response in SLE Patients After Vaccination Against SARS-CoV-2

**Authors:** Michał Komorniczak, Katarzyna Aleksandra Lisowska, Barbara Bułło-Piontecka, Alicja Dębska-Ślizień, Anna Wardowska

PMC · DOI: 10.3390/ijms262010241 · International Journal of Molecular Sciences · 2025-10-21

## TL;DR

This study examines immune responses in lupus patients after SARS-CoV-2 vaccination, finding distinct interferon and cytokine patterns but no significant boost in neutralizing antibodies.

## Contribution

The study identifies specific antiviral immune markers in SLE patients post-vaccination, focusing on interferon and cytokine profiles.

## Key findings

- Fully vaccinated SLE patients showed elevated type I and III interferons and pro-inflammatory cytokines.
- Neutralizing antibody levels against SARS-CoV-2 variants were similar between fully and partially vaccinated patients.
- ISG15 gene expression was upregulated in T cells of fully vaccinated patients.

## Abstract

Patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) are at increased risk of severe infections, making effective vaccination strategies essential. While antibody responses to SARS-CoV-2 vaccination have been studied in SLE, less is known about innate immune correlates. Therefore, we evaluated cytokines with a particular emphasis on interferon and chemokine profiles. To fulfill the immunological picture, we also assessed neutralizing antibodies against SARS-CoV-2 variants, lymphocyte subpopulations, and selected gene expression signatures in 33 patients stratified by vaccination status: fully vaccinated (FV, n = 23) and partially vaccinated (PV, n = 10). Serum analyses showed that FV patients exhibited increased type I (IFN-α2, IFN-β) and type III (IFN-λ1, IFN-λ2/3) interferons, as well as elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-12p70) and IL-10, whereas neutralizing antibody (Neut. Ab.) titers against wild-type and variant strains, including Omicron, were comparable between groups. Immunophenotyping demonstrated preserved T- and B-cell subset distributions, except for reduced CD8+CD197+CD45RA− (central memory) T cells in FV patients. ISG15 gene expression was upregulated in the T cells of FV patients. Correlation analyses linked IL-6 with disease activity and IL-8, GM-CSF, IFN-β, IL-10, and Alpha Neut. Ab. with organ damage. Complement C3 correlated inversely with IFN-α2 and IFN-γ, while C4 correlated positively with Alpha and Omicron Neut. Ab. These findings highlight that vaccination in SLE induces distinct interferon and cytokine signatures without consistent enhancement of neutralizing antibodies against SARS-CoV-2, underscoring the importance of integrated immune correlates in assessing vaccine responses in this population.

## Linked entities

- **Genes:** ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636]
- **Proteins:** IFNA2 (interferon alpha 2), IFNB1 (interferon beta 1), IFNL1 (interferon lambda 1), IL1B (interleukin 1 beta), IL6 (interleukin 6), TNF (tumor necrosis factor), IL10 (interleukin 10), CXCL8 (C-X-C motif chemokine ligand 8), CSF2 (colony stimulating factor 2), IFNG (interferon gamma), C3 (complement C3), C4A (complement C4A (Chido/Rodgers blood group))
- **Diseases:** systemic lupus erythematosus (MONDO:0007915), lupus nephritis (MONDO:0005556), SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Genes:** IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IFNL1 (interferon lambda 1) [NCBI Gene 282618] {aka IL-29, IL29}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, IFNA2 (interferon alpha 2) [NCBI Gene 3440] {aka IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** organ damage (MESH:D000092124), inflammatory cytokines (MESH:D000080424), FV (MESH:D004673), SLE (MESH:D008180), LN (MESH:D008181), infections (MESH:D007239)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12563841/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12563841/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12563841/full.md

---
Source: https://tomesphere.com/paper/PMC12563841